Stephen S. Raab

Stephen S. Raab

Auto-generated profile, based on publicly available information

Stephen S. Raab

Reprints: Stephen S. Raab, MD, Director of Cytology and Outcomes Research, Department of Pathology and Laboratory Medicine, and Co-Director of the Division of Clinical Effectiveness and Outcomes Research, Allegheny General Hospital, Medical College of Pennsylvania and Hahnemann University School of Medicine, 320 E North Ave, Pittsburgh, PA 15212-4772

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2000 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
SRStephen S. Raab
Stephen S. Raab
Objective. —To evaluate the cost-effectiveness of immunohistochemistry. Design. —Using a theoretical decision analytic model, the cost-effectiveness of immunohistochemistry was evaluated in different scenarios depicting the beneficial use of immunohistochemistry. Data regarding the effectiveness of immunohistochemistry were obtained from the medical literature and costs were obtained from Allegheny General Hospital. Settings. —The scenarios depicted both private practice and university patients from which anatomic pathology specimens were obtained. Immunohistochemistry was subsequently performed on these specimens. Main Outcome Measures. —Cost, life expectancy, diagnostic certainty, ability to predict prognosis, and cost-effectiveness were evaluated. Results. —In all scenarios, immunohistochemistry was cost-effective at very low efficacies. Assuming a per-antibody cost of $50 and use of a 5-antibody panel, immunohistochemistry was cost-effective if it resulted in a 1-year gain of population life expectancy in 1 or more of every 200 cases in which it was applied. Alternatively, if the gain in diagnostic certainty by using immunohistochemistry was 10% and the value placed on a percentage gain in diagnostic certainty was $1000, immunohistochemistry was cost-effective if it produced this increase in certainty in 1 of every 40 tests. If a life-year was valued at $50 000, immunohistochemistry was cost-effective if it resulted in a change in patient prognosis of 0.5 years in 1 of every 100 tests. Conclusions. —Using theoretical modeling, immunohistochemistry is extremely cost-effective. These data have implications in an era of managed care when providers attempt to trim laboratory services. Additional studies are needed to evaluate the actual practice efficacy of immunohistochemistry.

5 July 2000 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
SRStephen S. Raab
Stephen S. Raab

1 March 1998 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
SRStephen S. Raab
Stephen S. Raab
DSDaniel D. Slagel
Daniel D. Slagel
RRRobert A. Robinson
Robert A. Robinson
Stological study, and the clinical course were determined for all joints. Degenerative joint disease, rheumatoid arthritis, and avascular necrosis accounted for 98 per cent of the histological diagnoses. There were sixteen discrepancies between the clinical and histological diagnoses. The histological diagnosis did not affect the treatment of fifteen of these joints. However, the treatment was altered for one joint that had a clinical diagnosis of degenerative joint disease and a histological diagnosis of osteomyelitis; on review, the initial histological diagnosis was determined to be incorrect. In 1996 dollars, the cost of histological examination for all 168 joints was $10,698.24. Although there would be considerable cost-savings on a population basis if histological examination were not performed, this savings must be weighed against the effect of a misdiagnosis on the management of a particular patient....

1 September 1998 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
SRStephen S. Raab
Stephen S. Raab
Although the histologic examination of routine tissues, such as hernia sacs and intervertebral disks, has shown a low incidence of detecting clinically significant unsuspected disease, the cost-effectiveness of histologic examination has not been determined. By using a theoretical model that assumed variable costs and gains in life expectancy secondary to detecting clinically significant disease, a threshold incidence of disease detection at which histologic examination is cost-effective was determined. By using the University of Iowa (Iowa City) cost of examination (approximately $25), at least I of every 2,000 examinations would have to show clinically significant disease for histologic examination to be cost-effective. This threshold incidence decreases as production costs decrease or life-year values increase. Before definitive policy conclusions can be made, additional studies are needed to better define the trade-off between cost and the value of information and the incidence of detecting clinically significant disease.

1 August 2000
Verified
Journal Article
Closed access
SRS S Raab
S S Raab
To evaluate the cost-effectiveness of immunohistochemistry. Using a theoretical decision analytic model, the cost-effectiveness of immunohistochemistry was evaluated in different scenarios depicting the beneficial use of immunohistochemistry. Data regarding the effectiveness of immunohistochemistry were obtained from the medical literature and costs were obtained from Allegheny General Hospital. The scenarios depicted both private practice and university patients from which anatomic pathology specimens were obtained. Immunohistochemistry was subsequently performed on these specimens. Cost, life expectancy, diagnostic certainty, ability to predict prognosis, and cost-effectiveness were evaluated. In all scenarios, immunohistochemistry was cost-effective at very low efficacies. Assuming a per-antibody cost of $50 and use of a 5-antibody panel, immunohistochemistry was cost-effective if it resulted in a 1-year gain of population life expectancy in 1 or more of every 200 cases in which it was applied. Alternatively, if the gain in diagnostic certainty by using immunohistochemistry was 10% and the value placed on a percentage gain in diagnostic certainty was $1000, immunohistochemistry was cost-effective if it produced this increase in certainty in 1 of every 40 tests. If a life-year was valued at $50 000, immunohistochemistry was cost-effective if it resulted in a change in patient prognosis of 0.5 years in 1 of every 100 tests. Using theoretical modeling, immunohistochemistry is extremely cost-effective. These data have implications in an era of managed care when providers attempt to trim laboratory services. Additional studies are needed to evaluate the actual practice efficacy of immunohistochemistry.

1 September 1999 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
SRStephen S. Raab
Stephen S. Raab
NBN.SCott Bishop
N.SCott Bishop
MZM.SUe Zaleski
M.SUe Zaleski